

**VIL1 antibody - C-terminal region**  
**Rabbit Polyclonal Antibody**  
**Catalog # AI15181****Specification**

---

**VIL1 antibody - C-terminal region - Product Information**

Application	<b>WB</b>
Primary Accession	<a href="#">P09327</a>
Other Accession	<a href="#">NM_007127</a> , <a href="#">NP_009058</a>
Reactivity	<b>Human, Mouse, Rat, Rabbit, Horse, Bovine, Guinea Pig, Dog</b>
Predicted	<b>Human, Mouse, Rat, Rabbit, Pig, Horse, Bovine, Guinea Pig, Dog</b>
Host	<b>Rabbit</b>
Clonality	<b>Polyclonal</b>
Calculated MW	<b>93kDa KDa</b>

**VIL1 antibody - C-terminal region - Additional Information****Gene ID** 7429**Alias Symbol** **D2S1471, VIL**  
**Other Names**  
Villin-1, VIL1, VIL**Format**

Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.

**Reconstitution & Storage**

Add 50 ul of distilled water. Final anti-VIL1 antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles.

**Precautions**

VIL1 antibody - C-terminal region is for research use only and not for use in diagnostic or therapeutic procedures.

**VIL1 antibody - C-terminal region - Protein Information****Name** VIL1**Synonyms** VIL**Function**

Epithelial cell-specific Ca(2+)-regulated actin-modifying protein that modulates the reorganization of microvillar actin filaments. Plays a role in the actin nucleation, actin filament bundle assembly, actin filament capping and severing. Binds phosphatidylinositol 4,5-bisphosphate (PIP2) and lysophosphatidic acid (LPA); binds LPA with higher affinity than PIP2. Binding to LPA increases its phosphorylation by SRC and inhibits all actin-modifying activities. Binding to PIP2 inhibits

actin-capping and -severing activities but enhances actin-bundling activity. Regulates the intestinal epithelial cell morphology, cell invasion, cell migration and apoptosis. Protects against apoptosis induced by dextran sodium sulfate (DSS) in the gastrointestinal epithelium. Appears to regulate cell death by maintaining mitochondrial integrity. Enhances hepatocyte growth factor (HGF)-induced epithelial cell motility, chemotaxis and wound repair. Upon *S.flexneri* cell infection, its actin-severing activity enhances actin-based motility of the bacteria and plays a role during the dissemination.

#### Cellular Location

Cytoplasm, cytoskeleton. Cell projection, lamellipodium. Cell projection, ruffle. Cell projection, microvillus Cell projection, filopodium tip. Cell projection, filopodium. Note=Relocalized in the tip of cellular protrusions and filopodial extensions upon infection with *S.flexneri* in primary intestinal epithelial cells (IEC) and in the tail-like structures forming the actin comets of *S.flexneri*. Redistributed to the leading edge of hepatocyte growth factor (HGF)-induced lamellipodia (By similarity). Rapidly redistributed to ruffles and lamellipodia structures in response to autotaxin, lysophosphatidic acid (LPA) and epidermal growth factor (EGF) treatment.

#### Tissue Location


Specifically expressed in epithelial cells. Major component of microvilli of intestinal epithelial cells and kidney proximal tubule cells. Expressed in canalicular microvilli of hepatocytes (at protein level).

### VIL1 antibody - C-terminal region - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

### VIL1 antibody - C-terminal region - Images



WB Suggested Anti-VIL1 Antibody Titration: 1.0 µg/ml  
Positive Control: Fetal Liver

### VIL1 antibody - C-terminal region - References

Arpin M., et al. *J. Cell Biol.* 107:1759-1766(1988).

Ota T.,et al.Nat. Genet. 36:40-45(2004).  
Hillier L.W.,et al.Nature 434:724-731(2005).  
Mural R.J.,et al.Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.  
Pringault E.,et al.EMBO J. 5:3119-3124(1986).